Researchers believe that MS results when such components of the immune system attack both myelin, the fatty substance that insulates nerve fibers, and the nerve fibers themselves. Investigation of Novantrone for MS began in the late 1980s with studies, supported in part by the National MS Society, in animal models suggesting the drug could improve MS-like disease. The FDA based its decision on a series of clinical studies on Novantrone conducted over the past 10 years in Europe, which demonstrated benefit in slowing progression of disability, delaying and reducing frequency of relapses, and reducing accumulation of new lesions in the brain, detected by magnetic resonance imaging. Novantrone can increase the risk for infection, because it decreases the number of protective white blood cells. Prior to each dose of Novantrone, blood samples should be taken to check blood counts and liver function.
Cardiac monitoring is required.
For most, this would mean that after about 8 to 12 doses over 2 to 3 years, no more drug should be taken because of possible cardiac toxicity.